Rieken, Stefan

[["dc.bibliographiccitation.firstpage","3384"],["dc.bibliographiccitation.issue","14"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Leu, Martin"],["dc.contributor.author","Patzer, Christoph"],["dc.contributor.author","Guhlich, Manuel"],["dc.contributor.author","Possiel, Jacqueline"],["dc.contributor.author","Pilavakis, Yiannis"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.date.accessioned","2021-09-01T06:43:07Z"],["dc.date.available","2021-09-01T06:43:07Z"],["dc.date.issued","2021"],["dc.description.abstract","Locally advanced head and neck squamous cell carcinomas (HNSCC) are often managed with surgery followed by postoperative radiochemotherapy (RCT). With the general increase in life expectancy, the proportion of elderly patients with HNSCC is expected to grow rapidly. Until now, a deeper understanding of specific management strategies for these patients in clinical routine was lacking. In the present study, we compared elderly patients (≥70 years, n = 52) and younger patients (n = 245) treated with postoperative RCT for HNSCC at our tertiary cancer center. All patients were irradiated with modern radiotherapy techniques (IMRT/VMAT). Patients ≥70 years of age had more comorbidities. Additionally, elderly patients less frequently received concomitant systemic treatment. The rates of mucositis and dermatitis were lower in patients ≥70 years. Elderly patients had significantly worse overall and progression-free survival. Locoregional and distant control were comparable in elderly and younger patients. In conclusion, postoperative RCT is a safe and effective treatment option in patients ≥70 years. In light of comorbidities and poor overall survival rates, benefits and harms of radiotherapy and concomitant systemic treatment should be weighed carefully. When exclusively applying up-to-date radiotherapy techniques with, at the same time, careful use of concomitant systemic therapy, favorable acute toxicity profiles are achieved."],["dc.description.abstract","Locally advanced head and neck squamous cell carcinomas (HNSCC) are often managed with surgery followed by postoperative radiochemotherapy (RCT). With the general increase in life expectancy, the proportion of elderly patients with HNSCC is expected to grow rapidly. Until now, a deeper understanding of specific management strategies for these patients in clinical routine was lacking. In the present study, we compared elderly patients (≥70 years, n = 52) and younger patients (n = 245) treated with postoperative RCT for HNSCC at our tertiary cancer center. All patients were irradiated with modern radiotherapy techniques (IMRT/VMAT). Patients ≥70 years of age had more comorbidities. Additionally, elderly patients less frequently received concomitant systemic treatment. The rates of mucositis and dermatitis were lower in patients ≥70 years. Elderly patients had significantly worse overall and progression-free survival. Locoregional and distant control were comparable in elderly and younger patients. In conclusion, postoperative RCT is a safe and effective treatment option in patients ≥70 years. In light of comorbidities and poor overall survival rates, benefits and harms of radiotherapy and concomitant systemic treatment should be weighed carefully. When exclusively applying up-to-date radiotherapy techniques with, at the same time, careful use of concomitant systemic therapy, favorable acute toxicity profiles are achieved."],["dc.identifier.doi","10.3390/cancers13143384"],["dc.identifier.pii","cancers13143384"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/89222"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-455"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Postoperative Radiochemotherapy Using Modern Radiotherapy Techniques in Elderly Patients with Head and Neck Squamous Cell Carcinoma: The Challenge of Weighing Up Benefits and Harms of Treatment Modalities in Clinical Practice"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2805"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Leu, Martin"],["dc.contributor.author","Riebeling, Theresa"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.contributor.author","Hubert, Laura"],["dc.contributor.author","Guhlich, Manuel"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Brockmöller, Jürgen"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.date.accessioned","2021-07-05T15:00:42Z"],["dc.date.available","2021-07-05T15:00:42Z"],["dc.date.issued","2021"],["dc.description.abstract","Despite excellent loco-regional control by multimodal treatment of locally advanced rectal cancer, a substantial portion of patients succumb to this disease. As many treatment effects are mediated via reactive oxygen species (ROS), we evaluated the effect of single nucleotide polymorphisms (SNPs) in ROS-related genes on clinical outcome. Based on the literature, eight SNPs in seven ROS-related genes were assayed. Eligible patients (n = 287) diagnosed with UICC stage II/III rectal cancer were treated multimodally starting with neoadjuvant radiochemotherapy (N-RCT) according to the clinical trial protocols of CAO/ARO/AIO-94, CAO/ARO/AIO-04, TransValid-A, and TransValid-B. The median follow-up was 64.4 months. The Ser326Cys polymorphism in the human OGG1 gene affected clinical outcome, in particular cancer-specific survival (CSS). This effect was comparable in extent to the ypN status, an already established strong prognosticator for patient outcome. Homozygous and heterozygous carriers of the Cys326 variant (n = 105) encountered a significantly worse CSS (p = 0.0004 according to the log-rank test, p = 0.01 upon multiple testing adjustment). Cox regression elicited a hazard ratio for CSS of 3.64 (95% confidence interval 1.70–7.78) for patients harboring the Cys326 allele. In a multivariable analysis, the effect of Cys326 on CSS was preserved. We propose the genetic polymorphism Ser326Cys as a promising biomarker for outcome in rectal cancer."],["dc.description.abstract","Despite excellent loco-regional control by multimodal treatment of locally advanced rectal cancer, a substantial portion of patients succumb to this disease. As many treatment effects are mediated via reactive oxygen species (ROS), we evaluated the effect of single nucleotide polymorphisms (SNPs) in ROS-related genes on clinical outcome. Based on the literature, eight SNPs in seven ROS-related genes were assayed. Eligible patients (n = 287) diagnosed with UICC stage II/III rectal cancer were treated multimodally starting with neoadjuvant radiochemotherapy (N-RCT) according to the clinical trial protocols of CAO/ARO/AIO-94, CAO/ARO/AIO-04, TransValid-A, and TransValid-B. The median follow-up was 64.4 months. The Ser326Cys polymorphism in the human OGG1 gene affected clinical outcome, in particular cancer-specific survival (CSS). This effect was comparable in extent to the ypN status, an already established strong prognosticator for patient outcome. Homozygous and heterozygous carriers of the Cys326 variant (n = 105) encountered a significantly worse CSS (p = 0.0004 according to the log-rank test, p = 0.01 upon multiple testing adjustment). Cox regression elicited a hazard ratio for CSS of 3.64 (95% confidence interval 1.70–7.78) for patients harboring the Cys326 allele. In a multivariable analysis, the effect of Cys326 on CSS was preserved. We propose the genetic polymorphism Ser326Cys as a promising biomarker for outcome in rectal cancer."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft"],["dc.identifier.doi","10.3390/cancers13112805"],["dc.identifier.pii","cancers13112805"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/87886"],["dc.language.iso","en"],["dc.notes.intern","DOI Import DOI-Import GROB-441"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","8-Oxoguanine DNA Glycosylase (OGG1) Cys326 Variant: Increased Risk for Worse Outcome of Patients with Locally Advanced Rectal Cancer after Multimodal Therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Cancer"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Bozorgmehr, Farastuk"],["dc.contributor.author","Chung, Inn"],["dc.contributor.author","Christopoulos, Petros"],["dc.contributor.author","Krisam, Johannes"],["dc.contributor.author","Schneider, Marc A."],["dc.contributor.author","Brückner, Lena"],["dc.contributor.author","Mueller, Daniel Wilhelm"],["dc.contributor.author","Thomas, Michael"],["dc.contributor.author","Rieken, Stefan"],["dc.date.accessioned","2021-04-14T08:23:57Z"],["dc.date.available","2021-04-14T08:23:57Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1186/s12885-020-07264-8"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17530"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81111"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1471-2407"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","1011"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Cancer"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Bozorgmehr, Farastuk"],["dc.contributor.author","Christopoulos, Petros"],["dc.contributor.author","Chung, Inn"],["dc.contributor.author","Cvetkovic, Jelena"],["dc.contributor.author","Feißt, Manuel"],["dc.contributor.author","Krisam, Johannes"],["dc.contributor.author","Schneider, Marc A."],["dc.contributor.author","Heußel, Claus P."],["dc.contributor.author","Kreuter, Michael"],["dc.contributor.author","Müller, Daniel W."],["dc.contributor.author","Thomas, Michael"],["dc.contributor.author","Rieken, Stefan"],["dc.date.accessioned","2022-09-26T07:37:55Z"],["dc.date.available","2022-09-26T07:37:55Z"],["dc.date.issued","2022-09-24"],["dc.date.updated","2022-09-25T03:19:30Z"],["dc.description.abstract","Abstract\r\n \r\n Background\r\n Recently, the combination of the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab with first-line chemotherapy has demonstrated to improve outcome for patients with advanced small cell lung cancer (SCLC), leading to approval of this regimen. At the same time, accumulating (pre-)clinical data suggest synergisms of radiotherapy and immunotherapy via the radiation-mediated induction of anti-tumor immunogenicity. Combining the recent findings, the TREASURE trial aims at further enhancing response to upfront chemo-immunotherapy by the addition of thoracic radiotherapy (TRT).\r\n \r\n \r\n Methods/design\r\n The TREASURE trial is a randomized, multicenter, phase II clinical trial (\r\n ClinicalTrials.gov\r\n \r\n identifier, NCT04462276). One hundred four patients suffering from extensive disease (ED) SCLC, with any response to the standard of care induction chemo-immunotherapy will be randomized to receive atezolizumab maintenance therapy with or without TRT. The primary endpoint of this study is overall survival (OS). Secondary endpoints include further measures of efficacy, safety, and the collection of biomarker samples. A safety interim analysis will take place after n = 23 patients receiving TRT have been observed for three months after the end of TRT.\r\n \r\n \r\n Discussion\r\n This trial will investigate whether treatment efficacy can be improved by adding TRT to atezolizumab maintenance therapy in ED SCLC patients with any response after chemo-immunotherapy. Safety and feasibility of such a regimen will be evaluated, and biomaterials for a translational research project will be collected. Together, the results of this trial will deepen our comprehension of how checkpoint inhibition and radiotherapy interact and contribute to the evolving landscape of SCLC therapy.\r\n \r\n \r\n Trial registration\r\n \r\n\r\n Clinicaltrials.gov\r\n \r\n identifier: \r\n NCT04462276\r\n \r\n (Date of initial registration: 8th July 2020), \r\n https://clinicaltrials.gov/ct2/show/NCT04462276\r\n \r\n \r\n Eudra-CT Number: 2019-003916-29 (Date of initial registration: 30th March 2020), \r\n https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003916-29/DE"],["dc.identifier.citation","BMC Cancer. 2022 Sep 24;22(1):1011"],["dc.identifier.doi","10.1186/s12885-022-10074-9"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/114285"],["dc.language.iso","en"],["dc.rights","CC BY 4.0"],["dc.rights.holder","The Author(s)"],["dc.subject","Extensive disease small cell lung cancer"],["dc.subject","SCLC"],["dc.subject","Radioimmuntherapy"],["dc.subject","Thoracic radiotherapy"],["dc.subject","Atezolizumab"],["dc.subject","Anti-PD-L1 monoclonal antibody"],["dc.subject","First-line therapy"],["dc.title","Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease – a randomized, open-label, multicenter phase II trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1301"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","14"],["dc.contributor.affiliation","Flebbe, Hannah; 1Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany; hannah.flebbe@med.uni-goettingen.de (H.F.); melanie.spitzner@med.uni-goettingen.de (M.S.); pmarquet@tabea-krankenhaus.de (P.E.M.); jochen.gaedcke@med.uni-goettingen.de (J.G.); mghadim@uni-goettingen.de (B.M.G.); guenter.schneider@med.uni-goettingen.de (G.S.)"],["dc.contributor.affiliation","Spitzner, Melanie; 1Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany; hannah.flebbe@med.uni-goettingen.de (H.F.); melanie.spitzner@med.uni-goettingen.de (M.S.); pmarquet@tabea-krankenhaus.de (P.E.M.); jochen.gaedcke@med.uni-goettingen.de (J.G.); mghadim@uni-goettingen.de (B.M.G.); guenter.schneider@med.uni-goettingen.de (G.S.)"],["dc.contributor.affiliation","Marquet, Philipp Enno; 1Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany; hannah.flebbe@med.uni-goettingen.de (H.F.); melanie.spitzner@med.uni-goettingen.de (M.S.); pmarquet@tabea-krankenhaus.de (P.E.M.); jochen.gaedcke@med.uni-goettingen.de (J.G.); mghadim@uni-goettingen.de (B.M.G.); guenter.schneider@med.uni-goettingen.de (G.S.)"],["dc.contributor.affiliation","Gaedcke, Jochen; 1Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany; hannah.flebbe@med.uni-goettingen.de (H.F.); melanie.spitzner@med.uni-goettingen.de (M.S.); pmarquet@tabea-krankenhaus.de (P.E.M.); jochen.gaedcke@med.uni-goettingen.de (J.G.); mghadim@uni-goettingen.de (B.M.G.); guenter.schneider@med.uni-goettingen.de (G.S.)"],["dc.contributor.affiliation","Ghadimi, B. Michael; 1Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany; hannah.flebbe@med.uni-goettingen.de (H.F.); melanie.spitzner@med.uni-goettingen.de (M.S.); pmarquet@tabea-krankenhaus.de (P.E.M.); jochen.gaedcke@med.uni-goettingen.de (J.G.); mghadim@uni-goettingen.de (B.M.G.); guenter.schneider@med.uni-goettingen.de (G.S.)"],["dc.contributor.affiliation","Rieken, Stefan; 3Department of Radiotherapy and Radiooncology, University Medical Center Goettingen, 37075 Goettingen, Germany; stefan.rieken@med.uni-goettingen.de"],["dc.contributor.affiliation","Schneider, Günter; 1Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany; hannah.flebbe@med.uni-goettingen.de (H.F.); melanie.spitzner@med.uni-goettingen.de (M.S.); pmarquet@tabea-krankenhaus.de (P.E.M.); jochen.gaedcke@med.uni-goettingen.de (J.G.); mghadim@uni-goettingen.de (B.M.G.); guenter.schneider@med.uni-goettingen.de (G.S.)"],["dc.contributor.affiliation","Koenig, Alexander O.; 4Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, Germany; alexander.koenig@med.uni-goettingen.de"],["dc.contributor.affiliation","Grade, Marian; 1Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany; hannah.flebbe@med.uni-goettingen.de (H.F.); melanie.spitzner@med.uni-goettingen.de (M.S.); pmarquet@tabea-krankenhaus.de (P.E.M.); jochen.gaedcke@med.uni-goettingen.de (J.G.); mghadim@uni-goettingen.de (B.M.G.); guenter.schneider@med.uni-goettingen.de (G.S.)"],["dc.contributor.author","Flebbe, Hannah"],["dc.contributor.author","Spitzner, Melanie"],["dc.contributor.author","Marquet, Philipp Enno"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Schneider, Günter"],["dc.contributor.author","Koenig, Alexander O."],["dc.contributor.author","Grade, Marian"],["dc.date.accessioned","2022-04-01T10:00:34Z"],["dc.date.available","2022-04-01T10:00:34Z"],["dc.date.issued","2022"],["dc.date.updated","2022-04-08T08:31:13Z"],["dc.description.abstract","The debate is ongoing regarding the potential role of preoperative chemoradiotherapy (CRT) for patients with pancreatic ductal adenocarcinoma (PDAC), and whether it should be reserved for borderline resectable or unresectable tumors. However, treatment response is heterogeneous, implicating the need to unveil and overcome the underlying mechanisms of resistance. Activation of the transcription factor STAT3 was recently linked to CRT resistance in other gastrointestinal cancers such as rectal and esophageal cancers, but its role in PDAC needs to be clarified. Protein expression and phosphorylation of STAT3 was determined in PDAC cell lines and connected to transcriptional activity measured by dual-luciferase reporter gene assays. Inhibition of STAT3 signaling was achieved by RNAi or the small-molecule inhibitor napabucasin. We observed a positive correlation between STAT3 signaling activity and CRT resistance. Importantly, genetical and pharmacological perturbation of the IL-6/STAT3 pathway resulted in CRT sensitization specifically in those cell lines, in which STAT3 activity was augmented by IL-6. In conclusion, our data underscore the general importance of IL-6/STAT3 signaling for CRT resistance and suggest that pathway inhibition may represents a putative treatment strategy in order to increase the fraction of patients with PDAC who are candidates for surgical approaches."],["dc.identifier.doi","10.3390/cancers14051301"],["dc.identifier.pii","cancers14051301"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105459"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","2072-6694"],["dc.rights","Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)."],["dc.title","Targeting STAT3 Signaling Facilitates Responsiveness of Pancreatic Cancer Cells to Chemoradiotherapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2533"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Possiel, Jacqueline"],["dc.contributor.author","Ammon, Hanne Elisabeth"],["dc.contributor.author","Guhlich, Manuel"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Ghadimi, Michael"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Samel, Stephan"],["dc.contributor.author","Mügge, Michael"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Leu, Martin"],["dc.date.accessioned","2021-07-05T15:00:42Z"],["dc.date.available","2021-07-05T15:00:42Z"],["dc.date.issued","2021"],["dc.description.abstract","Background: Intensity-modulated radiotherapy (IMRT) is the standard of care in chemoradiotherapy (CRT) for anal cancer. Until now, only a limited number of studies have analyzed the results with VMAT (volumetric modulated arc therapy). We conducted a retrospective study on patients treated at our institution. Patients and Methods: We included patients who received curative CRT for anal cancer. We compared VMAT-treated and 3DCRT (3D conformal radiotherapy)-treated patients. We analyzed toxicities (acute: CTCAE criteria; late: LENT/SOMA criteria), treatment compliance, overall survival, cancer-specific survival (CSS), distant control (DC), and locoregional control. Results: A total of 149 patients (3DCRT: n = 87, VMAT: n = 62) were included. The median follow-up was longer in 3DCRT-treated patients (3DCRT: 61.3 months; VMAT: 39.1 months; p < 0.05). VMAT-treated patients had more G3 tumors (3DCRT: 12/87 (13.8%); VMAT: 18/62 (29.0%), p < 0.001). VMAT reduced acute toxicities ≥grade 3 (3DCRT: n = 48/87 (55.2%); VMAT: n = 11/62 (17.7%), p < 0.001). VMAT improved treatment compliance (less interruptions/delays) (3DCRT: 37/87, 42.5%; VMAT: 4/62, 6.5%; p < 0.001), provided a shorter median overall treatment time (3DCRT: 41 days; VMAT: 38 days; p = 0.02), and gave a higher median absolute 5-fluorouracil dose (3DCRT: 13,700 mg; VMAT: 14,400 mg; p = 0.001). Finally, we found improved CSS (p = 0.02; 3DCRT: 81.9% at 3 years; VMAT: 94.1% at 3 years) and DC (p = 0.01; 3DCRT: 89.4% at 3 years; VMAT: 100.0% at 3 years) with VMAT. Summary: Our study is the first to demonstrate improved treatment compliance and outcomes with VMAT for anal cancer. Previous studies have indicated that organs at risk sparing might be more improved with the use of VMAT vs. with conventional IMRT. Future studies should address whether these advantages lead to a further reduction in CRT-associated morbidity."],["dc.description.abstract","Background: Intensity-modulated radiotherapy (IMRT) is the standard of care in chemoradiotherapy (CRT) for anal cancer. Until now, only a limited number of studies have analyzed the results with VMAT (volumetric modulated arc therapy). We conducted a retrospective study on patients treated at our institution. Patients and Methods: We included patients who received curative CRT for anal cancer. We compared VMAT-treated and 3DCRT (3D conformal radiotherapy)-treated patients. We analyzed toxicities (acute: CTCAE criteria; late: LENT/SOMA criteria), treatment compliance, overall survival, cancer-specific survival (CSS), distant control (DC), and locoregional control. Results: A total of 149 patients (3DCRT: n = 87, VMAT: n = 62) were included. The median follow-up was longer in 3DCRT-treated patients (3DCRT: 61.3 months; VMAT: 39.1 months; p < 0.05). VMAT-treated patients had more G3 tumors (3DCRT: 12/87 (13.8%); VMAT: 18/62 (29.0%), p < 0.001). VMAT reduced acute toxicities ≥grade 3 (3DCRT: n = 48/87 (55.2%); VMAT: n = 11/62 (17.7%), p < 0.001). VMAT improved treatment compliance (less interruptions/delays) (3DCRT: 37/87, 42.5%; VMAT: 4/62, 6.5%; p < 0.001), provided a shorter median overall treatment time (3DCRT: 41 days; VMAT: 38 days; p = 0.02), and gave a higher median absolute 5-fluorouracil dose (3DCRT: 13,700 mg; VMAT: 14,400 mg; p = 0.001). Finally, we found improved CSS (p = 0.02; 3DCRT: 81.9% at 3 years; VMAT: 94.1% at 3 years) and DC (p = 0.01; 3DCRT: 89.4% at 3 years; VMAT: 100.0% at 3 years) with VMAT. Summary: Our study is the first to demonstrate improved treatment compliance and outcomes with VMAT for anal cancer. Previous studies have indicated that organs at risk sparing might be more improved with the use of VMAT vs. with conventional IMRT. Future studies should address whether these advantages lead to a further reduction in CRT-associated morbidity."],["dc.identifier.doi","10.3390/cancers13112533"],["dc.identifier.pii","cancers13112533"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/87885"],["dc.language.iso","en"],["dc.notes.intern","DOI Import DOI-Import GROB-441"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Volumetric Modulated Arc Therapy Improves Outcomes in Definitive Radiochemotherapy for Anal Cancer Whilst Reducing Acute Toxicities and Increasing Treatment Compliance"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3538"],["dc.bibliographiccitation.issue","14"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Weusthof, Katharina"],["dc.contributor.author","Lüttich, Peggy"],["dc.contributor.author","Regnery, Sebastian"],["dc.contributor.author","König, Laila"],["dc.contributor.author","Bernhardt, Denise"],["dc.contributor.author","Witt, Olaf"],["dc.contributor.author","Herfarth, Klaus"],["dc.contributor.author","Unterberg, Andreas"],["dc.contributor.author","Jungk, Christine"],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","Farnia, Benjamin"],["dc.contributor.author","Combs, Stephanie E."],["dc.contributor.author","Debus, Jürgen"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Harrabi, Semi"],["dc.date.accessioned","2021-08-12T07:45:53Z"],["dc.date.available","2021-08-12T07:45:53Z"],["dc.date.issued","2021"],["dc.description.abstract","Advanced radiation techniques can reduce the severity of neurocognitive sequelae in young brain tumor patients. In the present analysis, we sought to compare neurocognitive outcomes after proton irradiation with patients who underwent photon radiotherapy (RT) and surgery. Neurocognitive outcomes were evaluated in 103 pediatric brain tumor patients (proton RT n = 26, photon RT n = 30, surgery n = 47) before and after treatment. Comparison of neurocognitive outcomes following different treatment modalities were analyzed over four years after treatment completion. Longitudinal analyses included 42 months of follow-up after proton RT and 55 months after photon RT and surgery. Neurocognitive assessment included standardized tests examining seven domains. A comparison of neurocognitive outcomes after RT (proton and photon with >90% additional surgery) and surgery showed no significant differences in any neurocognitive domain. Neurocognitive functioning tests after proton RT failed to identify alterations compared to baseline testing. Long-term follow up over four years after photon RT showed a decrease in non-verbal intelligence (−9.6%; p = 0.01) and visuospatial construction (−14.9%; p = 0.02). After surgery, there was a decline in non-verbal intelligence (−10.7%; p = 0.01) and processing speed (14.9%; p = 0.002). Differences in neurocognitive outcomes between RT and surgical cohorts in direct intermodal comparison at long-term follow-up were not identified in our study, suggesting that modern radiation therapy does not affect cognition as much as in the past. There were no alterations in long-term neurocognitive abilities after proton RT, whereas decline of processing speed, non-verbal intelligence, and visuospatial abilities were observed after both photon RT and surgery. Domains dependent on intact white matter structures appear particularly vulnerable to brain tumor treatment irrespective of treatment approach."],["dc.description.abstract","Advanced radiation techniques can reduce the severity of neurocognitive sequelae in young brain tumor patients. In the present analysis, we sought to compare neurocognitive outcomes after proton irradiation with patients who underwent photon radiotherapy (RT) and surgery. Neurocognitive outcomes were evaluated in 103 pediatric brain tumor patients (proton RT n = 26, photon RT n = 30, surgery n = 47) before and after treatment. Comparison of neurocognitive outcomes following different treatment modalities were analyzed over four years after treatment completion. Longitudinal analyses included 42 months of follow-up after proton RT and 55 months after photon RT and surgery. Neurocognitive assessment included standardized tests examining seven domains. A comparison of neurocognitive outcomes after RT (proton and photon with >90% additional surgery) and surgery showed no significant differences in any neurocognitive domain. Neurocognitive functioning tests after proton RT failed to identify alterations compared to baseline testing. Long-term follow up over four years after photon RT showed a decrease in non-verbal intelligence (−9.6%; p = 0.01) and visuospatial construction (−14.9%; p = 0.02). After surgery, there was a decline in non-verbal intelligence (−10.7%; p = 0.01) and processing speed (14.9%; p = 0.002). Differences in neurocognitive outcomes between RT and surgical cohorts in direct intermodal comparison at long-term follow-up were not identified in our study, suggesting that modern radiation therapy does not affect cognition as much as in the past. There were no alterations in long-term neurocognitive abilities after proton RT, whereas decline of processing speed, non-verbal intelligence, and visuospatial abilities were observed after both photon RT and surgery. Domains dependent on intact white matter structures appear particularly vulnerable to brain tumor treatment irrespective of treatment approach."],["dc.description.sponsorship","Dietmar Hopp Stiftung"],["dc.identifier.doi","10.3390/cancers13143538"],["dc.identifier.pii","cancers13143538"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/88566"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-448"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Neurocognitive Outcomes in Pediatric Patients Following Brain Irradiation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Leu, Martin"],["dc.contributor.author","Kitz, J."],["dc.contributor.author","Pilavakis, Y."],["dc.contributor.author","Hakroush, S."],["dc.contributor.author","Wolff, H. A."],["dc.contributor.author","Canis, M."],["dc.contributor.author","Rieken, S."],["dc.contributor.author","Schirmer, M. A."],["dc.date.accessioned","2021-06-01T09:41:42Z"],["dc.date.available","2021-06-01T09:41:42Z"],["dc.date.issued","2021"],["dc.description.abstract","Abstract Treatment of locally advanced, unresectable head and neck squamous cell carcinoma (HNSCC) often yields only modest results with radiochemotherapy (RCT) as standard of care. Prognostic features related to outcome upon RCT might be highly valuable to improve treatment. Monocarboxylate transporters-1 and -4 (MCT1/MCT4) were evaluated as potential biomarkers. A cohort of HNSCC patients without signs for distant metastases was assessed eliciting 82 individuals eligible whereof 90% were diagnosed with locally advanced stage IV. Tumor specimens were stained for MCT1 and MCT4 in the cell membrane by immunohistochemistry. Obtained data were evaluated with respect to overall (OS) and progression-free survival (PFS). Protein expression of MCT1 and MCT4 in cell membrane was detected in 16% and 85% of the tumors, respectively. Expression of both transporters was not statistically different according to the human papilloma virus (HPV) status. Positive staining for MCT1 (n = 13, negative in n = 69) strongly worsened PFS with a hazard ratio (HR) of 3.1 (95%-confidence interval 1.6–5.7, p < 0.001). OS was likewise affected with a HR of 3.8 (2.0–7.3, p < 0.001). Multivariable Cox regression confirmed these findings. We propose MCT1 as a promising biomarker in HNSCC treated by primary RCT."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.doi","10.1038/s41598-021-84019-w"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85012"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","2045-2322"],["dc.relation.orgunit","Klinik für Strahlentherapie und Radioonkologie"],["dc.rights","CC BY 4.0"],["dc.title","Monocarboxylate transporter-1 (MCT1) protein expression in head and neck cancer affects clinical outcome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1080"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Current Oncology"],["dc.bibliographiccitation.lastpage","1092"],["dc.bibliographiccitation.volume","29"],["dc.contributor.affiliation","Habermann, Felix-Nikolai Oschinka Jegor; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Schmitt, Daniela; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Failing, Thomas; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Fischer, Jann; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Ziegler, David Alexander; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Fischer, Laura Anna; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Alt, Niklas Josua; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Muster, Julian; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Donath, Sandra; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Hille, Andrea; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Schirmer, Markus Anton; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Guhlich, Manuel; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","El Shafie, Rami A.; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Rieken, Stefan; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Leu, Martin; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Dröge, Leif Hendrik; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.author","Habermann, Felix-Nikolai Oschinka Jegor"],["dc.contributor.author","Schmitt, Daniela"],["dc.contributor.author","Failing, Thomas"],["dc.contributor.author","Fischer, Jann"],["dc.contributor.author","Ziegler, David Alexander"],["dc.contributor.author","Fischer, Laura Anna"],["dc.contributor.author","Alt, Niklas Josua"],["dc.contributor.author","Muster, Julian"],["dc.contributor.author","Donath, Sandra"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Guhlich, Manuel"],["dc.contributor.author","El Shafie, Rami A."],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Leu, Martin"],["dc.date.accessioned","2022-04-01T10:00:26Z"],["dc.date.available","2022-04-01T10:00:26Z"],["dc.date.issued","2022"],["dc.date.updated","2022-09-03T12:11:44Z"],["dc.description.abstract","The pandemic raised a discussion about the postponement of medical interventions for non-small cell lung cancer (NSCLC). We analyzed the characteristics of pretreatment diagnostic assessment in the pandemic and the influence of diagnostic assessment on outcomes. A total of 96 patients with stereotactic body radiation therapy (SBRT) for NSCLC were included. The number of patients increased from mean 0.9 (2012–2019) to 1.45 per month in the COVID era (p < 0.05). Pandemic-related factors (contact reduction, limited intensive care unit resources) might have influenced clinical decision making towards SBRT. The time from pretreatment assessment (multidisciplinary tumor board decision, bronchoscopy, planning CT) to SBRT was longer during the COVID period (p < 0.05). Reduced services, staff shortage, or appointment management to mitigate infection risks might explain this finding. Overall survival, progression-free survival, locoregional progression-free survival, and distant progression-free survival were superior in patients who received a PET/CT scan prior to SBRT (p < 0.05). This supports that SBRT guidelines advocate the acquisition of a PET/CT scan. A longer time from PET/CT scan/conventional staging to SBRT (<10 vs. ≥10 weeks) was associated with worse locoregional control (p < 0.05). The postponement of diagnostic or therapeutic measures in the pandemic should be discussed cautiously. Patient- and tumor-related features should be evaluated in detail."],["dc.identifier.doi","10.3390/curroncol29020092"],["dc.identifier.pii","curroncol29020092"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105426"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1718-7729"],["dc.rights","CC BY 4.0"],["dc.title","Patterns of Pretreatment Diagnostic Assessment in Patients Treated with Stereotactic Body Radiation Therapy (SBRT) for Non-Small Cell Lung Cancer (NSCLC): Special Characteristics in the COVID Pandemic and Influence on Outcomes"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","5585"],["dc.bibliographiccitation.issue","21"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Guhlich, Manuel"],["dc.contributor.author","Hubert, Laura"],["dc.contributor.author","Mergler, Caroline Patricia Nadine"],["dc.contributor.author","Rave-Fraenk, Margret"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.contributor.author","Leu, Martin"],["dc.contributor.author","Schmidberger, Heinz"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.editor","Urbanucci, Alfonso"],["dc.date.accessioned","2022-01-11T14:07:50Z"],["dc.date.available","2022-01-11T14:07:50Z"],["dc.date.issued","2021"],["dc.description.abstract","Genetic variability in transforming growth factor beta pathway (TGFB) was suggested to affect adverse events of radiotherapy. We investigated comprehensive variability in TGFB1 (gene coding for TGFβ1 ligand) and TGFBR1 (TGFβ receptor-1) in relation to radiotoxicity. Prostate cancer patients treated with primary radiotherapy (n = 240) were surveyed for acute and late toxicity. Germline polymorphisms (n = 40) selected to cover the common genetic variability in TGFB1 and TGFBR1 were analyzed in peripheral blood cells. Human lymphoblastoid cell lines (LCLs) were used to evaluate a possible impact of TGFB1 and TGFBR1 genetic polymorphisms to DNA repair capacity following single irradiation with 3 Gy. Upon adjustment for multiplicity testing, rs10512263 in TGFBR1 showed a statistically significant association with acute radiation toxicity. Carriers of the Cytosine (C)-variant allele (n = 35) featured a risk ratio of 2.17 (95%-CI 1.41–3.31) for acute toxicity ≥ °2 compared to Thymine/Thymine (TT)-wild type individuals (n = 205). Reduced DNA repair capacity in the presence of the C-allele of rs10512263 might be a mechanistic explanation as demonstrated in LCLs following irradiation. The risk for late radiotoxicity was increased by carrying at least two risk genotypes at three polymorphic sites, including Leu10Pro in TGFB1. Via comprehensive genotyping of TGFB1 and TGFBR1, promising biomarkers for radiotoxicity in prostate cancer were identified."],["dc.description.abstract","Genetic variability in transforming growth factor beta pathway (TGFB) was suggested to affect adverse events of radiotherapy. We investigated comprehensive variability in TGFB1 (gene coding for TGFβ1 ligand) and TGFBR1 (TGFβ receptor-1) in relation to radiotoxicity. Prostate cancer patients treated with primary radiotherapy (n = 240) were surveyed for acute and late toxicity. Germline polymorphisms (n = 40) selected to cover the common genetic variability in TGFB1 and TGFBR1 were analyzed in peripheral blood cells. Human lymphoblastoid cell lines (LCLs) were used to evaluate a possible impact of TGFB1 and TGFBR1 genetic polymorphisms to DNA repair capacity following single irradiation with 3 Gy. Upon adjustment for multiplicity testing, rs10512263 in TGFBR1 showed a statistically significant association with acute radiation toxicity. Carriers of the Cytosine (C)-variant allele (n = 35) featured a risk ratio of 2.17 (95%-CI 1.41–3.31) for acute toxicity ≥ °2 compared to Thymine/Thymine (TT)-wild type individuals (n = 205). Reduced DNA repair capacity in the presence of the C-allele of rs10512263 might be a mechanistic explanation as demonstrated in LCLs following irradiation. The risk for late radiotoxicity was increased by carrying at least two risk genotypes at three polymorphic sites, including Leu10Pro in TGFB1. Via comprehensive genotyping of TGFB1 and TGFBR1, promising biomarkers for radiotoxicity in prostate cancer were identified."],["dc.identifier.doi","10.3390/cancers13215585"],["dc.identifier.pii","cancers13215585"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/97876"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-507"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)."],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Identification of Risk Loci for Radiotoxicity in Prostate Cancer by Comprehensive Genotyping of TGFB1 and TGFBR1"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]